Cargando…
Assessing the Accuracy, Quality, and Readability of Patient Accessible Online Resources Regarding Ocular Gene Therapy and Voretigene Neparvovec
PURPOSE: To evaluate the accuracy, quality, and readability of online information regarding the Food and Drug Administration (FDA) approved ocular gene therapy voretigene neparvovec (Luxturna, Spark Therapeutics, Philadelphia, PA, USA). METHODS: Ten online resources about voretigene neparvovec were...
Autores principales: | Davuluri, Swetha, Yannuzzi, Nicolas A, Kloosterboer, Amy, Kuriyan, Ajay E, Sridhar, Jayanth |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8455297/ https://www.ncbi.nlm.nih.gov/pubmed/34556973 http://dx.doi.org/10.2147/OPTH.S324231 |
Ejemplares similares
-
Voretigene neparvovec for inherited retinal dystrophy
Publicado: (2021) -
Voretigene Neparvovec in Retinal Diseases: A Review of the Current Clinical Evidence
por: Gao, Jie, et al.
Publicado: (2020) -
Chorioretinal atrophy following voretigene neparvovec despite the presence of fundus autofluorescence
por: Kolesnikova, Masha, et al.
Publicado: (2022) -
Voretigene Neparvovec and Gene Therapy for Leber’s Congenital Amaurosis: Review of Evidence to Date
por: Padhy, Srikanta Kumar, et al.
Publicado: (2020) -
Spatial and temporal resolution of the photoreceptors rescue dynamics after treatment with voretigene neparvovec
por: Stingl, Krunoslav, et al.
Publicado: (2022)